Natalie Bareis, PhD, LMSW
- Assistant Professor of Clinical Behavioral Medicine (in Psychiatry)
Overview
My unique background working with individuals with schizophrenia and bipolar spectrum disorders and those experiencing long term homelessness as a social worker paired with my advanced biostatistical training as a psychiatric epidemiologist have given me the background and determination to use novel methods to identify efficacious pharmacologic and psychotherapeutic treatments for individuals with serious mental illness with a focus not only on treating symptoms but also improving quality of life.
Academic Appointments
- Assistant Professor of Clinical Behavioral Medicine (in Psychiatry)
Gender
- Female
Credentials & Experience
Education & Training
- Fellowship: T32 Postdoctoral Research Fellow, Late Life NeuroPsychiatric Disorders Research Training Program
Honors & Awards
Dr. Herbert Pardes Scholars Award, Columbia University (2026)
Brain & Behavior Research Foundation NARSAD Young Investigator Award (2026), Columbia University
Phi Kappa Phi Scholarly Achievement Award, Virginia Commonwealth University School of Medicine
Paige E. Cook Jr. Fellowship, Columbia University School of Social Work
Research
My clinical work and expertise in epidemiological and biostatistical methods have informed multiple studies using the NIMH Data Archive (NDA) and large nationally representative datasets (the CDC’s National Health and Nutrition Examination Survey (NHANES), the Health and Retirement Study (HRS), the National Comorbidity Survey Replication (NCS-R)). In addition, I was project manager of the Columbia University site of the Mental and Substance Use Disorders Prevalence Study (MDPS), a novel nationally representative psychiatric epidemiological survey with a primary focus on identifying up-to-date prevalence estimates of schizophrenia spectrum disorders in the US population. My current work utilizing national Medicaid claims data that identified variation in prescribing patterns of psychotropics for individuals with schizophrenia spectrum disorders between states, as well as identifying means of suicide among this population, and clozapine prescription, has laid the foundation for my K23 award. In that project I am using machine learning methods with claims and electronic health record data to identify unique clinical characteristics, or profiles, of individuals that are associated with heterogeneous responses to treatments prescribed for schizophrenia spectrum disorders. Using these data-driven methods we are identifying personalized treatment rules that predict outcomes of clinical importance to individuals receiving these treatments to ensure a patient-centered perspective that aligns with the heart of social work.
Grants
Brain & Behavior Research Foundation – Young Investigator Award
01/15/26-01/14-2028 (Bareis)
Machine learning with administrative data to identify personalized treatments in bipolar disorder
1K23MH129628-01A1 (Bareis) – NIMH
Machine Learning for Precision Treatments in Schizophrenia
09/05/2022-08/31/2026
Role: Principal Investigator
1L30MH131131-01 (Bareis) – NIMH
Optimizing Personalized Treatments for Schizophrenia with Machine Learning
07/01/2022-06-30-2024
Role: Principal Investigator
NYS OMH (Bareis)
Clozapine Prescription for Persons with Schizophrenia After a Suicide Attempt
04/01/2022-03/31/2023
Role: Principal Investigator
5P50MH115843-02 Sub-Project 7576 (Stroup) – NIMH
04/01/2018-12/21/2021
Machine Learning: Optimizing Individualized Treatments for Schizophrenia with Administrative Data
Role: Principal Investigator
5P50MH115843-02 Sub-Project (Stroup) – NIMH
10/01/2021-12/31/2022
Impact of widespread shift to telehealth during COVID-19 pandemic on services received by Medicaid recipients with serious mental illness
Role: Principal Investigator
Selected Publications
Bareis N, Wang Y, Olfson M, Gerhard T, Dixon L, Stroup TS. Machine learning for novel phenotyping in schizophrenia. Schizophrenia Research; 2025; 285: 19-26. (doi: https://doi.org/10.1016/j.schres.2025.08.011)
Anglin D, Olfson M, Oh H, DeVylder J, Oluwoye O, van der Ven E, Dixon L, Stroup TS, Lewis Fernandez R, Bareis N. Neighborhood social vulnerability and racial disparities in schizophrenia spectrum disorder prevalence. American Journal of Psychiatry; 2025; 182: 850-860. (doi: https://doi.org/10.1176/appi.ajp.20240906)
Bareis N, Edlund M, Ringeisen H, Guyer H, Dixon LB, Olfson M, Smith TE, Chwastiak L, Monroe-DeVita M, Swartz M, Swanson J, Sinclair Hancq E, Geiger P, Kreski NT, Stroup TS. Characterizing Schizophrenia Spectrum Disorders Results of the U.S. Mental and Substance Use Disorders Prevalence Study (MDPS). Psychiatric Services 2025 Jan 1;76(1):2-12. (doi: https://doi.org/10.1176/appi.ps.20240138)
Bareis N, Olfson M, Dixon LB, Chwastiak L, Monroe-DeVita M, Edlund MJ, Gibbons RD, Kreski N, Gibbons RD, Kessler RC, Stroup TS. Clinical Characteristics and Functioning of Adults with Bipolar I Disorder: Evidence from the Mental and Substance Use Disorders Prevalence Study; Journal of Affective Disorders; 2024; 366: 317-325. (doi: https://doi.org/10.1016/j.jad.2024.08.133)
Bareis N, Tepper MC, Wang R, Tang F, Olfson M, Dixon LB, Kimhy D, Wall MM, Medalia A, Finnerty MT, Anderson A, and Smith TE. Engagement of individuals with serious mental illness in outpatient mental health services and telehealth use during the COVID-19 pandemic; Psychiatry Research; 2023; 329:115497 (doi: 10.1016/j.psychres.2023.115497)
Bareis N, Olfson M, Gerhard T, Rolin S, and Stroup TS. Means of suicide among adults with schizophrenia across the life span; Schizophrenia Research; 2023; 251: 82-90. (doi: 10.1016/j.schres.2022.12.004)
Bareis N, Olfson M, Wall MM, and Stroup TS. Variation in Psychotropic Medication Prescription for Adults with Schizophrenia in the United States; Psychiatric Services; 2022; 73: 492-500. (doi: 10.1176/appi.ps.202000932)
https://www.ncbi.nlm.nih.gov/myncbi/natalie.bareis.1/bibliography/public/